Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1993 Nov;36(6):373–380. doi: 10.1007/BF01742253

A mouse/human chimeric anti-(ganglioside GD3) antibody with enhanced antitumor activities

Kenya Shitara 1,✉, Yoshihisa Kuwana 1, Kazuyasu Nakamura 1, Yuko Tokutake 1, So Ohta 1, Hiromasa Miyaji 1, Mamoru Hasegawa 1, Nobuo Hanai 1
PMCID: PMC11038311  PMID: 8500110

Abstract

Ganglioside GD3, which is one of the major gangliosides expressed on the cell surface of human tumors of neuroectodermal origin has been focused on as a target molecule for passive immunotherapy. We have cloned the cDNA encoding the immunoglobulin light and heavy chains of an anti-GD3 monoclonal antibody KM641 (murine IgG3, κ), and constructed the chimeric genes by linking the cDNA fragments of the murine light and heavy variable regions to cDNA fragments of the human κ and γ1 constant regions, respectively. The transfer of these cDNA constructs into SP2/0 mouse myeloma cells resulted in the production of the chimeric antibody, designated KM871, that retained specific binding activity to GD3. Indirect immunofluorescence revealed the same staining pattern for chimeric KM871 and the mouse counterpart KM641 on GD3-expressing melanoma cells. When human serum and human peripheral blood mononuclear cells were used as effectors in complement-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity respectively, the chimeric KM871 was more effective in killing GD3-expressing tumor cells than was the mouse counterpart KM641. Intravenous injection of chimeric KM871 markedly suppressed tumor growth in nude mice. The chimeric KM871, having enhanced antitumor activities and less immunogenicity than the mouse counterpart, would be a useful agent for passive immunotherapy of human cancer.

Key words: Ganglioside, Melanoma, Chimeric antibody

References

  • 1.Bernhard H, Bauerschmitz J, Büschenfelde K-H, Dippold W. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues. Int J Cancer. 1992;51:568. doi: 10.1002/ijc.2910510411. [DOI] [PubMed] [Google Scholar]
  • 2.Cheresh DA, Harper JR, Schulz G, Reisfeld RA. Localization of the gangliosides GD2 and GD3 in adhesion plaques and on the surface of human melanoma cells. Proc Natl Acad Sci USA. 1984;81:5767. doi: 10.1073/pnas.81.18.5767. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Cheung NV, Lazarus H, Miraldi FD. Ganglioside GD2 specific monoclonal antibody 3F8: a phase-I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol. 1987;5:1430. doi: 10.1200/JCO.1987.5.9.1430. [DOI] [PubMed] [Google Scholar]
  • 4.Dippold W, Lloyd KO, Li LTC, Ikeda H, Oettgen HF, Old LJ. Cell-surface antigens of human malignant melanoma-definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci USA. 1980;77:6114. doi: 10.1073/pnas.77.10.6114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Ellison JW, Berson BJ, Hood LE. The nucleotide sequence of a human immunoglobulin Cγ1 gene. Nucleic Acids Res. 1982;10:4071. doi: 10.1093/nar/10.13.4071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hakimi J, Chizzonite R, Luke DR, Familletti PC, Bailon P, Kondas JA, Pilson RS, Lin P, Weber DV, Spence C, Mondini LJ, Tsien W-H, Levin JL, Gallati VH, Korn L, Waldmann TA, Queen C, Benjamin WR. Reduced immunogenicity and improved pharmacokinetics of humanized anti-Tac in cynomolgus monkeys. J Immunol. 1991;147:1352. [PubMed] [Google Scholar]
  • 7.Hanai N, Nores GA, MacLeod C, Torres-Mendez C-R, Hakomori S. Ganglioside-mediated modulation of cell growth. J Biol Chem. 1988;263:10915. [PubMed] [Google Scholar]
  • 8.Hanai N, Furuya A, Shitara K, Oda S, Yoshida H. Comparative studies on monoclonal antibodies raised against human gastric cancer for application to serum diagnosis of cancer. Anticancer Res. 1988;8:329. [PubMed] [Google Scholar]
  • 9.Hanai N, Shitara K, Furuya A, Yoshida H, Dohi T, Nudelman E, Hakomori S, Satoh S. Detailed characterization of reactivities of anti-gastric cancer monoclonal antibodies to carbohydrate antigen. Anticancer Res. 1990;10:1579. [PubMed] [Google Scholar]
  • 10.Hieter PA, Max EE, Seidman JG, Maizel JV, Jr, Leder P. Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments. Cell. 1980;22:197. doi: 10.1016/0092-8674(80)90168-3. [DOI] [PubMed] [Google Scholar]
  • 11.Hellström I, Brankovan V, Hellström KE. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA. 1985;82:1499. doi: 10.1073/pnas.82.5.1499. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Houghton AN, Mintzer D, Cordon-Cardo C, Welt S, Fliegel B, Vadham S, Carswell E, Melamed MR, Oettgen H, Old LJ. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase-I trial in patients with malignant melanoma. Proc Natl Acad Sci USA. 1985;82:1242. doi: 10.1073/pnas.82.4.1242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Irie RF, Morton DL. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside. Proc Natl Acad Sci USA. 1986;83:8694. doi: 10.1073/pnas.83.22.8694. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Irie RF, Matsuki T, Morton DL. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet. 1989;I:786. doi: 10.1016/s0140-6736(89)92606-8. [DOI] [PubMed] [Google Scholar]
  • 15.Jennemann R, Rodden A, Bauer BL, Mennel H-D, Wiegandt H. Glycosphingolipids of human gliomas. Cancer Res. 1990;50:7444. [PubMed] [Google Scholar]
  • 16.Kameyama K, Imai K, Itoh T, Taniguchi M, Miura K, Kurosawa Y. Convenient plasmid vectors for construction of chimeric mouse/human antibodies. FEBS Lett. 1989;244:301. doi: 10.1016/0014-5793(89)80550-2. [DOI] [PubMed] [Google Scholar]
  • 17.Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF. Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. JNCI. 1988;80:937. doi: 10.1093/jnci/80.12.937. [DOI] [PubMed] [Google Scholar]
  • 18.Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin-derived V lesions and T-cell receptorderived C lesions. Biochem Biophys Res Commun. 1987;149:960. doi: 10.1016/0006-291x(87)90502-x. [DOI] [PubMed] [Google Scholar]
  • 19.Liu AY, Robinson RR, Hellstrom KE, Murray ED, Jr, Chang CP, Hellstrom I. Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells. Proc Natl Acad Sci USA. 1987;84:3439. doi: 10.1073/pnas.84.10.3439. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci USA. 1989;86:4220. doi: 10.1073/pnas.86.11.4220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Miyaji H, Mizukami T, Hosoi S, Sato S, Fujiyoshi N, Itoh S. Expression of human beta-interferon in Namalwa KJM-1 which was adapted to serum-free medium. Cytotechnology. 1990;3:133. doi: 10.1007/BF00143675. [DOI] [PubMed] [Google Scholar]
  • 22.Miyaji H, Harada N, Mizukami T, Sato S, Fujiyoshi N, Itoh S. Efficient expression of human beta-interferon in Namalwa KJM-1 cells adapated to serum-free medium by a dhfr gene coamplification method. Cytotechnology. 1990;4:173. doi: 10.1007/BF00365098. [DOI] [PubMed] [Google Scholar]
  • 23.Müeller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382. [PubMed] [Google Scholar]
  • 24.Nudelman E, Hakomori S, Kannagi R, Levery S, Yeh M-Y, Hellström KE, Hellström I. Characterization of a human melanoma-associated ganglioside antigen defined by a monoclonal antibody, 4.2. J Biol Chem. 1982;257:12 752. [PubMed] [Google Scholar]
  • 25.Ohta S, Honda A, Tokutake T, Yoshida H, Hanai N (1993) Antitumor effects of a novel monoclonal antibody with high binding-affinity to ganglioside GD3. Cancer Immunol Immunother (in press) [DOI] [PMC free article] [PubMed]
  • 26.Portoukalian J, Zwingelstein G, Dore J. Lipid composition of human malignant melanoma tumors at various levels of malignant growth. Eur J Biochem. 1979;94:19. doi: 10.1111/j.1432-1033.1979.tb12866.x. [DOI] [PubMed] [Google Scholar]
  • 27.Pukel CS, Lloyd KO, Travassor R, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. J Exp Med. 1982;155:1133. doi: 10.1084/jem.155.4.1133. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Ravindranath MH, Tsuchida T, Morton DL, Irie RI. Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer. 1991;67:3029. doi: 10.1002/1097-0142(19910615)67:12<3029::aid-cncr2820671217>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  • 29.Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of expression in cultured cells and tissues. Cancer Res. 1985;45:4401. [PubMed] [Google Scholar]
  • 30.Rinflet A, Horne C, Bour H, Markers A, Dorrington KJ, Klein M. Isotype modulation of idiotypic expression in recombinant isotype variants of MOPC 315. J Immunol. 1990;145:925. [PubMed] [Google Scholar]
  • 31.Roeder W, Maki R, Traunecker A, Tonegawa S. Linkage of the four γ subclass heavy chain genes. Proc Natl Acad Sci USA. 1981;78:474. doi: 10.1073/pnas.78.1.474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Rosenberg JM, Sander DJ, Derango RE, Cheresh DA. Enzymatic basis for increased expression of GD3 on human melanoma cells derived from metastatic lesions. J Clin Lab Anal. 1988;2:91. [Google Scholar]
  • 33.Sakano H, Huppi K, Heinrich H, Tonegawa S. Sequences at the somatic recombination sites of immunoglobulin light-chain genes. Nature. 1979;280:288. doi: 10.1038/280288a0. [DOI] [PubMed] [Google Scholar]
  • 34.Steplewski Z, Sun LK, Shearman CW, Ghrayeb J, Daddona P, Koprowski H. Biological activity of human-mouse IgG1, IgG2, IgG3, and IgG4 chimeric monoclonal antibodies with antitumor specificity. Proc Natl Acad Sci USA. 1988;85:4852. doi: 10.1073/pnas.85.13.4852. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Tsuchida T, Saxton RE, Morton DL, Irie RF. Gangliosides of human melanoma. JNCI. 1987;78:45. doi: 10.1093/jnci/78.1.45. [DOI] [PubMed] [Google Scholar]
  • 36.Vadhan-Raj S, Cordon-Cardo C, Carswell E, Mintzer D, Dantis L, Duteau C, Templeton MA, Oettgen HF, Old LJ, Houghton AN. Phase-I trial of a mouse monoclonal against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. J Clin Oncol. 1988;6:1636. doi: 10.1200/JCO.1988.6.10.1636. [DOI] [PubMed] [Google Scholar]
  • 37.Winter G, Milstein C. Man-made antibodies. Nature. 1991;349:293. doi: 10.1038/349293a0. [DOI] [PubMed] [Google Scholar]
  • 38.Yates AJ, Thompson PK, Boesel CP, Albrightson C, Hart RW. Lipid composition of human neural tumors. J Lipid Res. 1979;20:428. [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES